Show simple item record

dc.contributor.authorLee, HK
dc.contributor.authorTang, JW-T
dc.contributor.authorLoh, TP
dc.contributor.authorHurt, AC
dc.contributor.authorOon, LL-E
dc.contributor.authorKoay, ES-C
dc.date.accessioned2021-02-04T01:03:15Z
dc.date.available2021-02-04T01:03:15Z
dc.date.issued2015-01-30
dc.identifierpii: PONE-D-14-45826
dc.identifier.citationLee, H. K., Tang, J. W. -T., Loh, T. P., Hurt, A. C., Oon, L. L. -E. & Koay, E. S. -C. (2015). Molecular Surveillance of Antiviral Drug Resistance of Influenza A/H3N2 Virus in Singapore, 2009-2013. PLOS ONE, 10 (1), https://doi.org/10.1371/journal.pone.0117822.
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11343/259251
dc.description.abstractAdamantanes and neuraminidase inhibitors (NAIs) are two classes of antiviral drugs available for the chemoprophylaxis and treatment of influenza infections. To determine the frequency of drug resistance in influenza A/H3N2 viruses in Singapore, large-scale sequencing of neuraminidase (NA) and matrix protein (MP) genes was performed directly without initial culture amplification. 241 laboratory-confirmed influenza A/H3N2 clinical samples, collected between May 2009 and November 2013 were included. In total, 229 NA (95%) and 241 MP (100%) complete sequences were obtained. Drug resistance mutations in the NA and MP genes were interpreted according to published studies. For the NAIs, a visual inspection of the aligned NA sequences revealed no known drug resistant genotypes (DRGs). For the adamantanes, the well-recognised S31N DRG was identified in all 241 MP genes. In addition, there was an increasing number of viruses carrying the combination of D93G+Y155F+D251V (since May 2013) or D93G (since March 2011) mutations in the NA gene. However, in-vitro NAI testing indicated that neither D93G+Y155F+D251V nor D93G alone conferred any changes in NAI susceptibility. Lastly, an I222T mutation in the NA gene that has previously been reported to cause oseltamivir-resistance in influenza A/H1N1/2009, B, and A/H5N1, was detected from a treatment-naïve patient. Further in-vitro NAI testing is required to confirm the effect of this mutation in A/H3N2 virus.
dc.languageEnglish
dc.publisherPUBLIC LIBRARY SCIENCE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleMolecular Surveillance of Antiviral Drug Resistance of Influenza A/H3N2 Virus in Singapore, 2009-2013
dc.typeJournal Article
dc.identifier.doi10.1371/journal.pone.0117822
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titlePLoS One
melbourne.source.volume10
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid1207803
melbourne.contributor.authorHurt, Aeron
dc.identifier.eissn1932-6203
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record